What Is an Institutional Biosafety Committee?
An Institutional Biosafety Committee (IBC) evaluates risks in gene therapy research to ensure safety and compliance with NIH guidelines. Learn when IBC review is needed.
An Institutional Biosafety Committee (IBC) evaluates risks in gene therapy research to ensure safety and compliance with NIH guidelines. Learn when IBC review is needed.
In a recent webinar, Advarra experts Constance Cullity and Michele Russell-Einhorn presented FDA Inspections of Clinical Investigators: Understanding the Process
In a recent blog, we described the complexity and uniqueness of Phase I clinical trials, outlining the fact that some
A key element to successful study startup is identifying efficiencies to help meet critical milestones. Engaging with research compliance experts
Explore Advarra’s Study Activation Report to uncover roadblocks, survey findings, and solutions to streamline clinical trial activation at sites.
Discover how Meridian partnered with Advarra to ensure safety and streamline gene therapy research, including swift IBC approvals in just four days.
According to the Association for Clinical Oncology, individuals who identify as African American or Black make up 13.4% of the
With gene therapy trials on the rise, sites must prepare biosafety protocols, facility standards, and partnerships to attract cutting-edge studies.
In a recent webinar, Advarra regulatory experts presented on the topic titled Institutional Responsibilities Under a Federalwide Assurance (FWA). Our
In clinical research, working with organizations that understand the ins and outs of the phase of your trial is key
In the race to address the COVID-19 pandemic, researchers have worked tirelessly the past year to produce a vaccine. Operation
A common trope in sci-fi movies involves concerns about potentially smashing into uncharted objects while traveling at warp speed or